SCHEMBL5887229

SCHEMBL5887229

COC1=C(c2ccc(OC)cc2)[CH]CC=C1c1ccc(C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.46
KMT2A Q03164 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ALOX5 P09917 2/20 0.39
RELA Q04206 1/20 0.39
BACE1 P56817 2/20 0.38
MAPT P10636 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
EGFR P00533 1/20 0.35
KDR P35968 1/20 0.35
ALKBH3 Q96Q83 1/20 0.35
MEN1 O00255 2/20 0.35
KDM4E B2RXH2 1/20 0.35
PKM P14618 1/20 0.35
MAPK1 P28482 1/20 0.35
MCL1 Q07820 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
PTPN1 P18031 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887283 0.94 BACE1 (0.42) KMT2ANPC1RAB9ABACE1MAPT
SCHEMBL4007569 0.94 ACHE (0.33) ACHEKMT2ANPC1RAB9AALOX5
SCHEMBL4808770 0.87 PTGS2 (0.35) KMT2AMAPTNPSR1MEN1TDP1
SCHEMBL5887134 0.87 ALOX5 (0.39) KMT2ANPC1RAB9AALOX5BACE1
SCHEMBL5887217 0.86 ACHE (0.47) ACHEKMT2ANPC1RAB9AALOX5
SCHEMBL5887387 0.85 LTA4H (0.51) KMT2ANPC1RAB9ABACE1MAPT
SCHEMBL5887070 0.84 ACHE (0.44) ACHEKMT2ANPC1RAB9AALOX5
SCHEMBL5887471 0.83 KIF11 (0.34) ACHENPC1RAB9ABACE1MAPT
SCHEMBL5887388 0.81 BACE1 (0.42) ACHEKMT2ANPC1RAB9ABACE1
SCHEMBL5887273 0.80 AHR (0.34) EGFRALKBH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7037931-B2 Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-02 US disclosed
US-20050026903-A1 CCK-1 receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-03 US disclosed
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders JONES TODD K (US) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020565-A1 Pyrazole compound; gastrointestinal disorders; central nervous system disorders CCKAR, CCKBR, NPY1R ACHE 915/4885KMT2A 2927/4885NPC1 1831/4885
US-20050026903-A1 CCK-1 receptor modulators CCKAR, CCKBR, GLP1R ACHE 3650/4885KMT2A 2877/4885NPC1 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.